Thorne HealthTech Bilan de santé

Santé financière contrôle des critères 5/6

Thorne HealthTech possède un total de capitaux propres de $155.3M et une dette totale de $25.0M, ce qui porte son ratio d'endettement à 16.1%. Son actif total et son passif total sont $282.5M et de $127.3M. L'EBIT de Thorne HealthTech est $14.0M ce qui fait que son ratio de couverture des intérêts 14.8. Elle dispose de liquidités et de placements à court terme de $17.1M.

Informations clés

16.1%

Ratio d'endettement

US$24.99m

Dette

Ratio de couverture des intérêts	14.8x
Argent liquide	US$17.09m
Fonds propres	US$155.26m
Total du passif	US$127.27m
Total des actifs	US$282.53m

Mises à jour récentes de la santé financière

Recent updates

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Aug 12

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Aug 09

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Jun 05

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Mar 23

Thorne HealthTech: Good Potential At A Low Price

Jan 11

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de THRN ( $135.5M ) dépassent ses passifs à court terme ( $56.2M ).

Passif à long terme: Les actifs à court terme de THRN ( $135.5M ) dépassent ses passifs à long terme ( $71.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de THRN ( 5.1% ) est considéré comme satisfaisant.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de THRN a diminué au cours des 5 dernières années.

Couverture de la dette: La dette de THRN est bien couverte par le flux de trésorerie opérationnel ( 86.1% ).

Couverture des intérêts: Les paiements d'intérêts de THRN sur sa dette sont bien couverts par l'EBIT ( 14.8 x couverture).

Thorne HealthTech Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Thorne Healthtech, Inc. Files Form 15

Thorne HealthTech's Common Stock To Be Delisted from Nasdaq Global Select Market

Thorne HealthTech Receives Non-Compliance Notice from Nasdaq

Recent updates

Thorne Appoints Mary Beech as Chief Growth Officer

Thorne Healthtech, Inc. Files Form 15

Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from NASDAQ Composite Index

Thorne HealthTech's Common Stock To Be Delisted from Nasdaq Global Select Market

Thorne HealthTech Receives Non-Compliance Notice from Nasdaq

Price target increased by 11% to US$8.36

Thorne Healthtech, Inc. Announces Resignation of Takeshi Minakata from the Board of Directors

Investor sentiment improves as stock rises 27%

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Thorne Healthtech, Inc. Provides Earnings Guidance for 2023

Thorne HealthTech, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target increased by 8.7% to US$7.50

Thorne HealthTech Reportedly Working with Bank to Explore Sale

Investor sentiment improves as stock rises 17%

Thorne HealthTech, Inc. (NASDAQ:THRN) Not Flying Under The Radar

First quarter 2023 earnings: EPS misses analyst expectations

Thorne HealthTech, Inc. Reaffirms Financial Guidance for the Full-Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. (NasdaqGS:THRN) acquired PreCon Health, Inc. from Eigenlyfe LLC for $5 million.

Investor sentiment improves as stock rises 15%

Thorne HealthTech, Inc. Announces Executive Changes

Investors Will Want Thorne HealthTech's (NASDAQ:THRN) Growth In ROCE To Persist

Investor sentiment improved over the past week

Thorne Healthtech's OneDraw Device Used in Department of Defense's Cancer Moonshot 2.0 Project, Prometheus, as Part of President Biden Initiative

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$7.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. Revises Net Sales Guidance for the Full Year 2022

Thorne HealthTech, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Thorne HealthTech Grows But Faces Macro Headwinds

Thorne Healthtech's OneDraw(TM) Blood Collection Device Receives PMDA Certification in Japan

Thorne HealthTech's blood collection device OneDraw gets clearance in Japan

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. Revises Sales Guidance for the Full-Year 2022

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Investor sentiment improved over the past week

Thorne HealthTech, Inc. Achieves Self-Affirmed GRAS Status for Nicotinamide Riboside Malate Product

Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from Russell 2500 Value Index

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Thorne HealthTech, Inc. Relaunches Gut Health Test

Thorne HealthTech, Inc. Relaunches Gut Health Test

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Thorne HealthTech, Inc. Reaffirms Sales Guidance for the Full-Year 2022

Thorne HealthTech, Inc., Annual General Meeting, Jun 02, 2022

Co-Founder exercised options to buy US$326k worth of stock.

Consensus forecasts updated

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Full year 2021 earnings: EPS misses analyst expectations

Thorne HealthTech: Good Potential At A Low Price

Forecast breakeven date pushed back to 2022

Forecast to breakeven in 2021

Thorne HealthTech, Inc. has completed an IPO in the amount of $70 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines